ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years
Chunhua She
Matched on OpenAlex author ID A5101197889, A5159598346. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 3
- The c-Myc-USP14-PFKP axis sustains chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2026.101385↗
- CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
- Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… Co-author DOI 10.1186/s13046-023-02814-x↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chao Xu · 2 shared papers, 2023–2025 · strength 0.34
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058↗
- Paper Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modula… DOI 10.1186/s13046-023-02814-x↗
- Xiuchao Wang · 2 shared papers, 2023–2025 · strength 0.34
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058↗
- Paper Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modula… DOI 10.1186/s13046-023-02814-x↗
- Yongjie Xie · 2 shared papers, 2023–2025 · strength 0.34
- Paper CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. DOI 10.20892/j.issn.2095-3941.2025.0058↗
- Paper Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modula… DOI 10.1186/s13046-023-02814-x↗
- Danqi Fu · 1 shared paper, 2026 · strength 0.24
- Jing Hu · 1 shared paper, 2026 · strength 0.24
- Pengyu Wang · 1 shared paper, 2026 · strength 0.24
- Shengyu Yang · 1 shared paper, 2025 · strength 0.18
- Guannan Sheng · 1 shared paper, 2025 · strength 0.18
- Liangliang Wu · 1 shared paper, 2025 · strength 0.18
- Chongbiao Huang · 1 shared paper, 2025 · strength 0.18
- Kaiyuan Wang · 1 shared paper, 2025 · strength 0.18
- Tiansuo Zhao · 1 shared paper, 2025 · strength 0.18
- Bo Ni · 1 shared paper, 2025 · strength 0.18
- Song Gao · 1 shared paper, 2025 · strength 0.18
- Tianxing Zhou · 1 shared paper, 2025 · strength 0.18
- Chao Wu · 1 shared paper, 2023 · strength 0.16
- Weishuai Liu · 1 shared paper, 2023 · strength 0.16
- Jihui Hao · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.